Immune cell therapy shows promise for tough cancers
NCT ID NCT03935893
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prepare their immune system, then get an infusion of their own TIL cells plus high-dose aldesleukin. The goal is to see if the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tumor-infiltrating lymphocytes (TIL) plus high-dose aldesleukin, after chemotherapy
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced solid cancers that have not responded to standard therapies.
- What could go wrong
- This is a small, early-phase trial (20 participants) with no control group. The treatment involves strong chemotherapy and high-dose aldesleukin, which can cause serious side effects. Success is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?